LLY (Eli Lilly and Company) Stock Financials & Earnings | Market Cap Arena

Market CapArena

LLY (Eli Lilly and Company) Stock Financials & Earnings | Market Cap Arena

LLYEli Lilly and Company

Mkt Cap$951B

LLYEli Lilly and Company

$951B

Company Info & Key Metrics

Healthcare Drug Manufacturers - General

Country🇺🇸 United States

ExchangeNYSE

Revenue$19.3B

YoY Growth+42.6%

QoQ Growth+9.6%

Net Income$6.6B

EPS$7.39

Free Cash Flow$678M

Gross Margin85.1%

Op. Margin45.5%

Net Margin34.4%

FCF Margin3.5%

Rev Multiple (TTM)14.6x

P/E Ratio (TTM)46.1x

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$7.0B	$5.3B	$1.7B
Q2 23	$8.3B	$6.5B	$2.3B
Q3 23	$9.5B	$7.6B	$3.5B
Q4 23	$9.4B	$7.6B	$3.2B
Q1 24	$8.8B	$7.1B	$2.7B
Q2 24	$11.3B	$9.1B	$4.4B
Q3 24	$11.4B	$9.3B	$4.5B
Q4 24	$13.5B	$11.1B	$5.8B
Q1 25	$12.7B	$10.5B	$5.4B
Q2 25	$15.6B	$13.1B	$7.1B
Q3 25	$17.6B	$14.6B	$8.4B
Q4 25	$19.3B	$16.4B	$8.8B

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	34.4x	167.3x
Q2 23	32.2x	146.4x
Q3 23	29.7x	190.7x
Q4 23	27.9x	181.5x
Q1 24	26.5x	155.0x
Q2 24	24.4x	129.6x
Q3 24	23.3x	113.7x
Q4 24	21.1x	89.8x
Q1 25	19.4x	85.7x
Q2 25	17.9x	68.9x
Q3 25	16.0x	51.7x
Q4 25	14.6x	46.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$1.7B	$827M
Q2 23	$632M	-$204M
Q3 23	$2.2B	-$1.8B
Q4 23	-$312M	-$2.0B
Q1 24	$1.2B	$180M
Q2 24	$1.5B	$63M
Q3 24	$3.7B	-$459M
Q4 24	$2.5B	$727M
Q1 25	$1.7B	-$1.6B
Q2 25	$3.1B	$1.3B
Q3 25	$8.8B	$8.6B
Q4 25	$3.2B	$678M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$904M
Q2 23	$836M
Q3 23	$4.0B
Q4 23	$1.7B
Q1 24	$986M
Q2 24	$1.4B
Q3 24	$4.2B
Q4 24	$1.7B
Q1 25	$3.3B
Q2 25	$1.8B
Q3 25	$224M
Q4 25	$2.5B

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-10.9%	+1.9%
Q2 23	+28.1%	+25.9%
Q3 23	+36.8%	+21.5%
Q4 23	+28.1%	+20.9%
Q1 24	+26.0%	+15.0%
Q2 24	+36.0%	+15.2%
Q3 24	+20.4%	+15.6%
Q4 24	+44.7%	+25.6%
Q1 25	+45.2%	+21.3%
Q2 25	+37.6%	+22.5%
Q3 25	+53.9%	+33.8%
Q4 25	+42.6%	+36.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$131M	1.9%
Q2 23	$162M	1.9%
Q3 23	$216M	2.3%
Q4 23	$120M	1.3%
Q1 24	$159M	1.8%
Q2 24	$211M	1.9%
Q3 24	$133M	1.2%
Q4 24	$142M	1.0%
Q1 25	$154M	1.2%
Q2 25	$185M	1.2%
Q3 25	$151M	0.9%
Q4 25	$136M	0.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$2.0B	$1.6B
Q2 23	$2.4B	$1.8B
Q3 23	$2.4B	$1.7B
Q4 23	$2.6B	$1.8B
Q1 24	$2.5B	$1.8B
Q2 24	$2.7B	$2.0B
Q3 24	$2.7B	$2.0B
Q4 24	$3.0B	$2.3B
Q1 25	$2.7B	$2.4B
Q2 25	$3.3B	$2.6B
Q3 25	$3.5B	$2.7B
Q4 25	$3.8B	$3.3B

Revenue Segments

Quarter	Diabetes	Immunology	Neuroscience	Oncology	Other Product, Total	Cardiometabolic Health
Q1 23	$4.2B	$778M	$361M	$1.4B	$275M	—
Q2 23	$5.0B	$929M	$387M	$1.7B	$315M	—
Q3 23	$4.7B	$987M	$1.8B	$1.7B	$276M	—
Q1 24	$5.5B	$834M	$553M	$2.1B	$242M	—
Q2 24	—	$1.1B	$487M	$2.5B	$208M	$7.5B
Q3 24	—	$1.2B	$469M	$2.6B	$263M	$7.4B
Q1 25	—	$1.1B	$272M	$1.9B	$213M	$9.2B
Q2 25	—	$1.3B	$344M	$2.4B	$202M	$11.3B
Q3 25	—	$1.4B	$316M	$2.4B	$337M	$13.2B

Revenue by Geography

Quarter	China	Europe	Japan	Non-US	United States
Q1 23	$373M	$1.1B	$387M	$673M	$4.4B
Q2 23	$399M	$1.2B	$456M	$749M	$5.5B
Q3 23	$391M	$2.6B	$391M	$780M	$5.4B
Q4 23	$377M	$1.3B	$439M	$744M	$6.5B
Q1 24	$376M	$1.4B	$364M	$893M	$5.7B
Q2 24	$395M	$1.4B	$463M	$1.2B	$7.8B
Q3 24	$460M	$1.6B	$429M	$1.1B	$7.8B
Q4 24	$429M	$2.4B	$559M	$1.1B	$9.0B
Q1 25	$451M	$2.4B	$402M	$997M	$8.5B
Q2 25	$466M	$2.6B	$521M	$1.2B	$10.8B
Q3 25	$560M	$3.5B	$555M	$1.7B	$11.3B
Q4 25	$474M	$3.1B	$654M	$2.2B	$12.9B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$3.5B	$123M	$3.7B
Q2 23	$2.7B	$135M	$2.8B
Q3 23	$2.4B	$113M	$2.5B
Q4 23	$2.8B	$109M	$2.9B
Q1 24	$2.5B	$126M	$2.6B
Q2 24	$3.2B	$140M	$3.4B
Q3 24	$3.4B	$149M	$3.5B
Q4 24	$3.3B	$155M	$3.4B
Q1 25	$3.1B	$127M	$3.2B
Q2 25	$3.4B	$170M	$3.5B
Q3 25	$9.8B	$122M	$9.9B
Q4 25	$7.2B	$105M	$7.3B

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	949M	-0.1%
Q2 23	949M	+0.0%
Q3 23	949M	+0.0%
Q4 23	904M	-4.8%
Q1 24	904M	-0.0%
Q2 24	904M	+0.0%
Q3 24	905M	+0.1%
Q4 24	903M	-0.2%
Q1 25	901M	-0.3%
Q2 25	900M	-0.1%
Q3 25	899M	-0.1%
Q4 25	898M	-0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$501K	39K
FY 15	$484K	41K
FY 16	$506K	42K
FY 17	$491K	41K
FY 18	$556K	39K
FY 19	$664K	34K
FY 20	$701K	35K
FY 21	$809K	35K
FY 22	$732K	39K
FY 23	$794K	43K
FY 24	$958K	47K
FY 25	$326K	200K